Trial Profile
A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Linrodostat (Primary) ; Nivolumab (Primary) ; BCG
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions
- Acronyms CheckMate 9UT
- Sponsors Bristol-Myers Squibb
- 03 May 2023 Status changed from completed to discontinued due to Insufficient Enrollment.
- 29 Sep 2022 Status changed from active, no longer recruiting to completed.
- 25 Sep 2022 This trial has been Completed in Netherlands, according to European Clinical Trials Database record.(Global end date 22-08-2022)